Expertise in
4
conditions

Dr. Anton P. Porsteinsson

University Of Rochester
Rochester, NY
Expertise in
4
conditions
Specialties:Psychiatry | Geriatrics
Expertise in
4
conditions
OverviewInsuranceLocationsClinical Research

Overview

Anton Porsteinsson is a Psychiatrist and a Geriatrics provider in Rochester, New York. Dr. Porsteinsson is highly rated in 4 conditions, according to our data. His top areas of expertise are Alzheimer's Disease, Dementia, Cerebellar Degeneration, and Neuronal Intranuclear Inclusion Disease (NIID).

His clinical research consists of co-authoring 96 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Psychiatry
Geriatrics
Licenses
Geriatric Psychiatry in NY
Hospital Affiliations
Strong Memorial Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Locations

UNIVERSITY OF ROCHESTER
601 Elmwood Ave, Rochester, NY 14642
585-275-2100

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Escitalopram for Agitation in Alzheimer's Disease
Escitalopram for Agitation in Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drug: Escitalopram
Study Phase: Phase 3
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
Therapeutic Effects of Intranasally-Administered Insulin in Adults With Amnestic Mild Cognitive Impairment (aMCI) or Mild Alzheimer's Disease (AD)
Therapeutic Effects of Intranasally-Administered Insulin in Adults With Amnestic Mild Cognitive Impairment (aMCI) or Mild Alzheimer's Disease (AD)
Enrollment Status: Completed
Publish Date: November 20, 2024
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 Mg Tablets in Subjects with Mild-to-Moderate Alzheimer's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 Mg Tablets in Subjects with Mild-to-Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: November 15, 2024
Intervention Type: Drug
Study Drug: Simufilam
Study Phase: Phase 3
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects with Mild to Moderate Alzheimer's Disease
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects with Mild to Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: November 15, 2024
Intervention Type: Drug
Study Drug: ATH-1017
Study Phase: Phase 2/Phase 3
SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD): A Multi-center, Randomized, Double-Blind, Placebo-Controlled Safety and Biomarker Study of Pepinemab Anti-SEMA4D Antibody in Early-AD
SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD): A Multi-center, Randomized, Double-Blind, Placebo-Controlled Safety and Biomarker Study of Pepinemab Anti-SEMA4D Antibody in Early-AD
Enrollment Status: Completed
Publish Date: August 22, 2024
Intervention Type: Drug
Study Drug: Pepinemab
Study Phase: Phase 1/Phase 2
Trial Ready Cohort for the Prevention of Alzheimer's Dementia (TRC-PAD)
Trial Ready Cohort for the Prevention of Alzheimer's Dementia (TRC-PAD)
Enrollment Status: Completed
Publish Date: June 27, 2024
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Enrollment Status: Completed
Publish Date: December 28, 2023
Intervention Type: Drug
Study Drug: Solanezumab
Study Phase: Phase 3
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: BIIB092
Study Phase: Phase 2
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 02, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer's Disease Dementia (Extension of Study AZES, The AMARANTH Study)
A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer's Disease Dementia (Extension of Study AZES, The AMARANTH Study)
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 3
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
View 11 Less Clinical Trials

96 Total Publications

Measuring clinically relevant change in apathy symptoms in ADMET and ADMET 2.
Measuring clinically relevant change in apathy symptoms in ADMET and ADMET 2.
Journal: International psychogeriatrics
Published: September 19, 2024
Similar Doctors
Expertise in
2
conditions
Dr. Robert A. Stern
Psychiatry
Expertise in
2
conditions
Dr. Robert A. Stern
Psychiatry
1425 Portland Ave, 
Rochester, NY 
 (5.2 mi)
585-922-4100
Languages Spoken:
English

Robert Stern is a Psychiatrist in Rochester, New York. Dr. Stern is highly rated in 2 conditions, according to our data. His top areas of expertise are Alzheimer's Disease, Dementia, and Traumatic Brain Injury.

Expertise in
9
conditions
Dr. Alexandra M. Fotiou
Psychiatry | Geriatrics
Expertise in
9
conditions
Dr. Alexandra M. Fotiou
Psychiatry | Geriatrics

University Of Rochester

738 Library Rd, 
Rochester, NY 
 (0.4 mi)
585-275-2638
Languages Spoken:
English
Offers Telehealth

Alexandra Fotiou is a Psychiatrist and a Geriatrics provider in Rochester, New York. Dr. Fotiou is highly rated in 9 conditions, according to our data. Her top areas of expertise are Schizoaffective Disorder, Bipolar Disorder (BPD), Post-Traumatic Stress Disorder (PTSD), and Schizophrenia.

Expertise in
7
conditions
Dr. M S. Ismail
Psychiatry | Geriatrics
Expertise in
7
conditions
Dr. M S. Ismail
Psychiatry | Geriatrics

Rochester General Hospital

224 Alexander St, 
Rochester, NY 
 (2.4 mi)
585-922-8400
Experience:
36+ years
Languages Spoken:
English

M Ismail is a Psychiatrist and a Geriatrics provider in Rochester, New York. Dr. Ismail has been practicing medicine for over 36 years is highly rated in 7 conditions, according to our data. His top areas of expertise are Bipolar Disorder (BPD), Schizoaffective Disorder, Schizophrenia, and Major Depression.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile